Breaking News Instant updates and real-time market news.

ACHN

Achillion

$4.01

0.04 (1.01%)

09:24
08/09/17
08/09
09:24
08/09/17
09:24

Achillion rises after reporting proof-of-concept data for factor D inhibitor

Shares of Achillion (ACHN) are higher in pre-market trading after the company said that it "believes" it has achieved the goal of achieving proof-of-concept for ACH-4471 via factor D inhibition. DATA: Last night, Achillion announced data from a phase 2 three-month, dose-ranging trial with ACH-4471 for patients with untreated PNH, a rare, acquired, life-threatening disease characterized by destruction of red blood cells, blood clots, impaired bone marrow function, and a risk of developing leukemia.. To date, Achillion has data for four patients with PNH, two of whom have completed the three-month trial and have entered the long-term extension trial. One additional patient continues to receive dosing in the three-month trial and a fourth patient voluntarily withdrew from the trial on day 41 for reasons unrelated to safety. In summary, interim data from these ongoing trials demonstrated that ACH-4471 achieved clinically meaningful complement inhibition and demonstrated a favorable tolerability profile with no reports of clinically meaningful increases in liver enzymes. In this emerging data set, ACH-4471 has improved LDH, hemoglobin, fatigue score and other measures of response including PNH clone size. These interim results support the company's global expansion plans for the PNH clinical program. "Our focus in early clinical development with ACH-4471 has been on achieving proof-of-concept via factor D inhibition, and we are pleased to report that we believe we have achieved this goal. The emerging interim results from our phase 2 PNH trial have demonstrated a dose response to treatment with what we believe to be meaningful improvements in LDH, hemoglobin, fatigue score and other markers of response. To date, orally administered ACH-4471 has been well tolerated in this PNH clinical trial with four patients enrolled and treated with ACH-4471, two of whom have now received more than four months of dosing," said CEO Milind Deshpande. PRICE ACTION: In pre-market trading, Achillion shares are up 79c, or about 20%, to $4.80.

ACHN Achillion
$4.01

0.04 (1.01%)

04/24/17
BARD
04/24/17
NO CHANGE
Target $5
BARD
Outperform
Achillion price target lowered to $5 from $10 at Baird
Baird analyst Brian Skorney lowered his price target on Achillion (ACHN) to $5 from $10 on its disappointing Hep-C results, which indicated a weakness when it comes to genotype 3 patients. Although he expects partner Johnson & Johnson (JNJ) to push the trial into Phase 3, he think it makes the regimen a more difficult sell with other drugs offering genotype 3 efficacy. Skorney maintained his Outperform rating on Achillion shares.
04/25/17
JMPS
04/25/17
NO CHANGE
JMPS
Johsnson &Johnson data positive for Achillion, says JMP Securities
JMP Securities analyst Liisa Bayko says that data on a triple combination HCV treatment presented by Johnson & Johnson (JNJ) yesterday is positive for Achillion (ACHN). The analyst noted that the triple combination includes Achillion's odalasvir and that the six week treatment regimen is shorter than the eight weeks required for Gilead's (GILD) Harvoni. The analyst says that Achillion's stock dropped sharply yesterday because there was disappointment over the combination's efficacy in genotype 3 patients. However, she says that such patients only represent 10% of the total, and she says that Achillion can "conservatively" obtain peak royalty revenue of about $100M from its drug. Bayko keeps a $13 price target and an Outperform rating on the shares.
04/25/17
MAXM
04/25/17
NO CHANGE
Target $5
MAXM
Buy
Achillion price target lowered to $5 from $8 at Maxim
Maxim analyst Jason Kolbert said phase 2 trial results demonstrated that Achillion's (ACHN) triple combination of simeprevir, odalasvir and AL-335 has the ability to shorten treatment duration, be generally well tolerated and offer high efficacy for hepatitis C virus genotype 1 patients. While Johnson & Johnson (JNJ) is likely to move forward with this regimen, allowing Achillion to realize milestones, Kolbert has removed any royalties from his model as he expects others to dominate the landscape with "near perfect" regimens. Kolbert lowered his price target on Achillion to $5 from $8 but keeps a Buy rating on the shares.
05/18/17
LEER
05/18/17
UPGRADE
Target $6
LEER
Outperform
Achillion upgraded to Outperform from Market Perform at Leerink
Leerink analyst Joseph Schwartz upgraded Achillion Pharmaceuticals (ACHN) and raised his price target for the shares to $6 from $4. The analyst sees limited downside from current share levels even if the complement study fails, assuming the hepatitis C virus partnership with Johnson & Johnson (JNJ) remains intact. Schwartz assigned a "conservative" 33% probability of success to Achillion's complement program due to the lack of precedent for an oral small molecule inhibitor of complement factor D that is selective enough to avoid off target effects. He believes risks to successful ACH-4471 development are fully discounted in Achillion's current stock price.

TODAY'S FREE FLY STORIES

BXP

Boston Properties

$122.03

-0.4 (-0.33%)

07:46
08/17/17
08/17
07:46
08/17/17
07:46
Downgrade
Boston Properties rating change  »

Boston Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LFC

China Life Insurance

$15.24

0.04 (0.26%)

07:46
08/17/17
08/17
07:46
08/17/17
07:46
Downgrade
China Life Insurance rating change  »

China Life Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSY

Hershey

$106.04

0.14 (0.13%)

07:46
08/17/17
08/17
07:46
08/17/17
07:46
Upgrade
Hershey rating change  »

Hershey upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RVLT

Revolution Lighting

$6.82

-0.03 (-0.44%)

07:42
08/17/17
08/17
07:42
08/17/17
07:42
Hot Stocks
Revolution Lighting awarded DoD contract »

Revolution Lighting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOLD

Amicus

$12.60

0.31 (2.52%)

, IRWD

Ironwood

$14.92

0.06 (0.40%)

07:42
08/17/17
08/17
07:42
08/17/17
07:42
Recommendations
Amicus, Ironwood, Otonomy, Sarepta, Ignyta analyst commentary  »

JPMorgan lists top SMID…

FOLD

Amicus

$12.60

0.31 (2.52%)

IRWD

Ironwood

$14.92

0.06 (0.40%)

OTIC

Otonomy

$19.35

-0.1 (-0.51%)

SRPT

Sarepta

$37.43

0.72 (1.96%)

RXDX

Ignyta

$9.80

0.1 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 26

    Sep

CSVI

Computer Services

$46.50

0.45 (0.98%)

07:41
08/17/17
08/17
07:41
08/17/17
07:41
Hot Stocks
Computer Services announces retirement of president R. Stanley Eckenberg »

Computer Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROIC

Retail Opportunity

$20.14

0.09 (0.45%)

07:40
08/17/17
08/17
07:40
08/17/17
07:40
Upgrade
Retail Opportunity rating change  »

Retail Opportunity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$159.50

1.75 (1.11%)

07:39
08/17/17
08/17
07:39
08/17/17
07:39
Hot Stocks
Alibaba: 'The numbers speak for themselves' »

Alibaba said on its Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 18

    Aug

AAPL

Apple

$160.94

-0.68 (-0.42%)

07:38
08/17/17
08/17
07:38
08/17/17
07:38
Periodicals
Apple Watch may not support voice calls at launch, AI reports »

The new LTE-connected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

WMT

Wal-Mart

$80.98

0.21 (0.26%)

07:35
08/17/17
08/17
07:35
08/17/17
07:35
Hot Stocks
Breaking Hot Stocks news story on Wal-Mart »

Wal-Mart drops 2.3% in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 16

    Nov

  • 20

    Feb

TDOC

Teladoc

$30.05

-1.15 (-3.69%)

07:35
08/17/17
08/17
07:35
08/17/17
07:35
Recommendations
Teladoc analyst commentary  »

Teladoc to benefit from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 06

    Sep

  • 11

    Sep

AERI

Aerie Pharmaceuticals

$52.20

-0.2 (-0.38%)

07:35
08/17/17
08/17
07:35
08/17/17
07:35
Recommendations
Aerie Pharmaceuticals analyst commentary  »

Aerie Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

  • 28

    Feb

BABA

Alibaba

$159.50

1.75 (1.11%)

, MU

Micron

$30.69

1.01 (3.40%)

07:35
08/17/17
08/17
07:35
08/17/17
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

BABA

Alibaba

$159.50

1.75 (1.11%)

MU

Micron

$30.69

1.01 (3.40%)

FCX

Freeport McMoRan

$14.77

0.8 (5.73%)

VALE

Vale

$10.10

0.32 (3.27%)

RIG

Transocean

$7.58

-0.33 (-4.17%)

MPC

Marathon Petroleum

$51.06

-0.83 (-1.60%)

COTY

Coty

$19.67

0.11 (0.56%)

PAGP

Plains GP Holdings

$20.35

-0.46 (-2.21%)

ETSY

Etsy

$15.60

-0.04 (-0.26%)

FOLD

Amicus

$12.60

0.31 (2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 18

    Aug

  • 22

    Aug

  • 29

    Aug

  • 29

    Aug

  • 06

    Sep

  • 08

    Nov

REG

Regency Centers

$65.52

0.46 (0.71%)

07:34
08/17/17
08/17
07:34
08/17/17
07:34
Upgrade
Regency Centers rating change  »

Regency Centers upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COMM

CommScope

$32.85

0.01 (0.03%)

07:34
08/17/17
08/17
07:34
08/17/17
07:34
Upgrade
CommScope rating change  »

CommScope upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

MSG

Madison Square Garden

$217.42

1.33 (0.62%)

07:33
08/17/17
08/17
07:33
08/17/17
07:33
Earnings
MSG reports Q4 EPS ($3.58), may not compare to consensus ($1.39) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

ARAY

Accuray

$4.00

-0.1 (-2.44%)

07:32
08/17/17
08/17
07:32
08/17/17
07:32
Hot Stocks
Accuray's Radixact system used by Summit Cancer Center-Boise for the first time »

Accuray and the Summit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

AMOV

America Movil, also tag AMX

$18.51

-0.07 (-0.38%)

, AMX

America Movil, also tag AMOV

$18.82

0.22 (1.18%)

07:32
08/17/17
08/17
07:32
08/17/17
07:32
Periodicals
Mexican Supreme Court rules for America Movil on interconnection fees, WSJ says »

Mexico's Supreme…

AMOV

America Movil, also tag AMX

$18.51

-0.07 (-0.38%)

AMX

America Movil, also tag AMOV

$18.82

0.22 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDEN

Golden Entertainment

$21.41

0.23 (1.09%)

07:31
08/17/17
08/17
07:31
08/17/17
07:31
Hot Stocks
Golden Entertainment completes syndication of financing to fund American deal »

Golden Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$8.65

0.06 (0.70%)

, CBI

CB&I

$9.97

-1.22 (-10.90%)

07:30
08/17/17
08/17
07:30
08/17/17
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

PBR

Petrobras

$8.65

0.06 (0.70%)

CBI

CB&I

$9.97

-1.22 (-10.90%)

URBN

Urban Outfitters

$19.76

2.94 (17.48%)

CL

Colgate-Palmolive

$71.93

0.13 (0.18%)

AXON

Axovant Sciences

$21.80

-0.83 (-3.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

CSCO

Cisco

$32.34

0.25 (0.78%)

07:28
08/17/17
08/17
07:28
08/17/17
07:28
Recommendations
Cisco analyst commentary  »

Cisco stock likely range…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

LB

L Brands

$38.95

0.5 (1.30%)

07:28
08/17/17
08/17
07:28
08/17/17
07:28
Recommendations
L Brands analyst commentary  »

L Brands share losses may…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

CSCO

Cisco

$32.34

0.25 (0.78%)

07:28
08/17/17
08/17
07:28
08/17/17
07:28
Recommendations
Cisco analyst commentary  »

Cisco 'slowly moving…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

CCL

Carnival

$68.87

0.16 (0.23%)

07:28
08/17/17
08/17
07:28
08/17/17
07:28
Recommendations
Carnival analyst commentary  »

Carnival price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTNA

Quantenna Communications

$17.79

-0.23 (-1.28%)

07:27
08/17/17
08/17
07:27
08/17/17
07:27
Conference/Events
Quantenna Communications management to meet with Deutsche Bank »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 23

    Aug

  • 12

    Sep

  • 08

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.